Ovarian cancer patient samples were analysed for cytokine concentration changes after adenovirus treatments, with or without anti-PD1/anti-PD-L1 (pembrolizumab and atezolizumab) (Figure 2). Here, PDCD1 is linked to ovarian carcinoma.